Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Santen Oy1 site in 1 country150 target enrollmentJanuary 2008

ConditionsOcular Hypertension Open-Angle Glaucoma

Interventionstafluprost

Drugstafluprost

Overview

Phase: Phase 3
Intervention: tafluprost
Conditions: Ocular Hypertension
Sponsor: Santen Oy
Enrollment: 150
Locations: 1
Primary Endpoint: Change from screening in ocular symptoms and signs
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Registry

clinicaltrials.gov

Start Date

January 2008

End Date

August 2008

Last Updated

17 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Santen Oy

Eligibility Criteria

Inclusion Criteria

•Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.